全文获取类型
收费全文 | 777篇 |
免费 | 52篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 75篇 |
妇产科学 | 16篇 |
基础医学 | 104篇 |
口腔科学 | 19篇 |
临床医学 | 102篇 |
内科学 | 132篇 |
皮肤病学 | 2篇 |
神经病学 | 148篇 |
特种医学 | 32篇 |
外科学 | 94篇 |
综合类 | 5篇 |
预防医学 | 33篇 |
眼科学 | 1篇 |
药学 | 35篇 |
肿瘤学 | 42篇 |
出版年
2021年 | 5篇 |
2020年 | 12篇 |
2019年 | 7篇 |
2018年 | 8篇 |
2017年 | 9篇 |
2016年 | 9篇 |
2015年 | 7篇 |
2014年 | 11篇 |
2013年 | 36篇 |
2012年 | 29篇 |
2011年 | 26篇 |
2010年 | 14篇 |
2009年 | 23篇 |
2008年 | 37篇 |
2007年 | 40篇 |
2006年 | 33篇 |
2005年 | 24篇 |
2004年 | 28篇 |
2003年 | 22篇 |
2002年 | 22篇 |
2001年 | 40篇 |
2000年 | 58篇 |
1999年 | 39篇 |
1998年 | 27篇 |
1997年 | 25篇 |
1996年 | 13篇 |
1995年 | 10篇 |
1994年 | 11篇 |
1993年 | 8篇 |
1992年 | 29篇 |
1991年 | 18篇 |
1990年 | 7篇 |
1989年 | 11篇 |
1988年 | 18篇 |
1987年 | 15篇 |
1986年 | 12篇 |
1985年 | 11篇 |
1984年 | 11篇 |
1983年 | 8篇 |
1982年 | 7篇 |
1981年 | 4篇 |
1980年 | 4篇 |
1979年 | 7篇 |
1978年 | 7篇 |
1977年 | 7篇 |
1975年 | 4篇 |
1974年 | 6篇 |
1973年 | 3篇 |
1972年 | 4篇 |
1971年 | 3篇 |
排序方式: 共有841条查询结果,搜索用时 31 毫秒
831.
832.
JA Povlsen B Løfgren LE Rasmussen JM Nielsen R Nørregaard SB Kristiansen HE Bøtker TT Nielsen 《Clinical and experimental pharmacology & physiology》2009,36(9):892-898
- 1 Because diabetic hearts have an increased threshold for cardioprotection by ischaemic preconditioning (IPC), we hypothesized that protection by l ‐glutamate during reperfusion is restricted in Type 2 diabetic hearts. Previously, we found that l ‐glutamate‐mediated postischaemic cardioprotection mimics IPC.
- 2 Rat hearts were studied in a Langendorff preparation perfused with Krebs’–Henseleit solution and subjected to 40 min global no‐flow ischaemia, followed by 120 min reperfusion. l ‐Glutamate (0, 15 and 30 mmol/L) was added to the perfusate during reperfusion of hearts from non‐diabetic (Wistar‐Kyoto) and diabetic (Zucker diabetic fatty (ZDF)) rats, studied at 16 weeks of age. The infarct size (IS)/area‐at‐risk (AAR) ratio was the primary end‐point. Expression of l ‐glutamate excitatory amino acid transporter (EAAT) 1 (mitochondrial) and EAAT3 (sarcolemmal) was determined by quantitative polymerase chain reaction and immunoblotting.
- 3 The ISS/AAR ratio did not differ between control hearts from Wistar‐Kyoto and ZDF rats (0.52 ± 0.03 and 0.51 ± 0.04, respectively; P = 0.90). l ‐Glutamate (15 mmol/L) significantly reduced the IS/AAR ratio in non‐diabetic hearts, but not in diabetic hearts, compared with their respective controls. The higher concentration of l ‐glutamate (30 mmol/L) reduced infarct size in diabetic hearts to the same degree as in non‐diabetic hearts (IS/AAR 0.35 ± 0.03 (P = 0.002) and 0.34 ± 0.03 (P = 0.004), respectively). The mitochondrial l ‐glutamate transporter EAAT1 was downregulated in hearts from ZDF rats at both the mRNA and protein levels (P < 0.0005 and P < 0.0001, respectively). However, there was no change in EAAT3 expression at the protein level. Myocardial l ‐glutamate content was increased by 43% in diabetic hearts (P < 0.0001).
- 4 Hearts from obese diabetic rats have an elevated threshold for metabolic postischaemic cardioprotection by l ‐glutamate. These findings may reflect underlying mechanisms of inherent resistance against additional cardioprotection in the diabetic heart.
833.
Ruiz C Holz DR Oeggerli M Schneider S Gonzales IM Kiefer JM Zellweger T Bachmann A Koivisto PA Helin HJ Mousses S Barrett MT Azorsa DO Bubendorf L 《The Journal of pathology》2011,223(4):543-552
Androgen withdrawal is the standard treatment for advanced prostate cancer. Although this therapy is initially effective, nearly all prostate cancers become refractory to it. Approximately 15% of these castration-resistant prostate cancers harbour a genomic amplification at 10q22. The aim of this study was to explore the structure of the 10q22 amplicon and to determine the major driving genes. Application of high-resolution array-CGH using the 244k Agilent microarrays to cell lines with 10q22 amplification allowed us to narrow down the common amplified region to a region of 5.8 megabases. We silenced each of the genes of this region by an RNAi screen in the prostate cancer cell lines PC-3 and 22Rv1. We selected genes with a significant growth reduction in the 10q22 amplified cell line PC-3, but not in the non-amplified 22Rv1 cells, as putative target genes of this amplicon. Immunohistochemical analysis of the protein expression of these candidate genes on a tissue microarray enriched for 10q22 amplified prostate cancers revealed vinculin as the most promising target of this amplicon. We found a strong association between vinculin gene amplification and overexpression (p < 0.001). Further analysis of 443 specimens from across all stages of prostate cancer progression showed that vinculin expression was highest in castration-resistant prostate cancers, but negative or very low in benign prostatic hyperplasia (p < 0.0001). Additionally, high tumour cell proliferation measured by Ki67 expression was significantly associated with high vinculin expression in prostate cancer (p < 0.0001). Our data suggest that vinculin is a major driving gene of the 10q22 amplification in prostate cancer and that vinculin overexpression might contribute to prostate cancer progression by enhancing tumour cell proliferation. 相似文献
834.
Salminen-Vaparanta N Noreika V Revonsuo A Koivisto M Vanni S 《Human brain mapping》2012,33(3):652-665
The primary visual cortex (V1) has been the target of stimulation in a number of transcranial magnetic stimulation (TMS) studies. In this study, we estimated the actual sites of stimulation by modeling the cortical location of the TMS-induced electric field when participants reported visual phosphenes or scotomas. First, individual retinotopic areas were identified by multifocal functional magnetic resonance imaging (mffMRI). Second, during the TMS stimulation, the cortical stimulation sites were derived from electric field modeling. When an external anatomical landmark for V1 was used (2 cm above inion), the cortical stimulation landed in various functional areas in different individuals, the dorsal V2 being the most affected area at the group level. When V1 was specifically targeted based on the individual mffMRI data, V1 could be selectively stimulated in half of the participants. In the rest, the selective stimulation of V1 was obstructed by the intermediate position of the dorsal V2. We conclude that the selective stimulation of V1 is possible only if V1 happens to be favorably located in the individual anatomy. Selective and successful targeting of TMS pulses to V1 requires MRI-navigated stimulation, selection of participants and coil positions based on detailed retinotopic maps of individual functional anatomy, and computational modeling of the TMS-induced electric field distribution in the visual cortex. It remains to be resolved whether even more selective stimulation of V1 could be achieved by adjusting the coil orientation according to sulcal orientation of the target site. 相似文献
835.
836.
837.
838.
839.
Mattila AK Poutanen O Koivisto AM Salokangas RK Joukamaa M 《General hospital psychiatry》2008,30(1):77-79
OBJECTIVE: The objective of this study was to examine how the outcomes of a structured diagnostic interview for depression are related to the results of a self-report scale in alexithymic and nonalexithymic groups. MATERIALS AND METHODS: Subjects (N=389) recruited from primary care and psychiatric care completed the Depression Scale (DEPS) and the 20-item Toronto Alexithymia Scale. Major depression was diagnosed using the Composite International Diagnostic Interview-Short-Form by telephone. RESULTS: In the group without major depression, the DEPS scores of the alexithymic subjects were significantly higher than those of the nonalexithymic subjects. In the group with major depression, the ideal cutoff points of the DEPS, assessed by receiver operating characteristic analyses, were essentially higher for the alexithymic patients. CONCLUSIONS: Alexithymic subjects without major depression may be rated as depressive if the only criterion is the score on a self-report scale. Furthermore, alexithymic patients may require higher cutoff points in a self-report depression scale. 相似文献
840.
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B 总被引:47,自引:0,他引:47
Klunk WE Engler H Nordberg A Wang Y Blomqvist G Holt DP Bergström M Savitcheva I Huang GF Estrada S Ausén B Debnath ML Barletta J Price JC Sandell J Lopresti BJ Wall A Koivisto P Antoni G Mathis CA Långström B 《Annals of neurology》2004,55(3):306-319
This report describes the first human study of a novel amyloid-imaging positron emission tomography (PET) tracer, termed Pittsburgh Compound-B (PIB), in 16 patients with diagnosed mild AD and 9 controls. Compared with controls, AD patients typically showed marked retention of PIB in areas of association cortex known to contain large amounts of amyloid deposits in AD. In the AD patient group, PIB retention was increased most prominently in frontal cortex (1.94-fold, p = 0.0001). Large increases also were observed in parietal (1.71-fold, p = 0.0002), temporal (1.52-fold, p = 0.002), and occipital (1.54-fold, p = 0.002) cortex and the striatum (1.76-fold, p = 0.0001). PIB retention was equivalent in AD patients and controls in areas known to be relatively unaffected by amyloid deposition (such as subcortical white matter, pons, and cerebellum). Studies in three young (21 years) and six older healthy controls (69.5 +/- 11 years) showed low PIB retention in cortical areas and no significant group differences between young and older controls. In cortical areas, PIB retention correlated inversely with cerebral glucose metabolism determined with 18F-fluorodeoxyglucose. This relationship was most robust in the parietal cortex (r = -0.72; p = 0.0001). The results suggest that PET imaging with the novel tracer, PIB, can provide quantitative information on amyloid deposits in living subjects. 相似文献